MBX Biosciences, Inc. (MBX) Stock Analysis: An 88.72% Potential Upside Fuels Investor Optimism
MBX Biosciences, Inc. (MBX) stands at the forefront of the biotechnology industry with its focus on precision peptide ...
Model output · Signal date 2026-10-16
Mbx Biosciences, Inc. (MBX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Top 35%
of 5184 stocks scored
Rank correlation · 90D
5.0%
Spearman, 238 dates
Market Cap
$2.39B
mid-cap · #60 of 60 peers
Summary
Mbx Biosciences, Inc. (MBX) stock forecast summary
Our AI ranks Mbx Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Mbx Biosciences, Inc. is a mid-cap company with a market capitalization of $2.39B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For MBX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 5.0%, measured on 238 forecast dates between 2024-11-08 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 281 forecast dates between 2024-11-08 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MBX included.
Follow MBX freePrice
MBX price chart and AI forecast
Cross-section · 2026-10-16
How MBX ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Mbx Biosciences, Inc. (MBX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | MBX | Rank |
|---|---|---|
| Market Cap | $2.39B | 60/60 |
| P/B Ratio | 5.83x | 27/42 |
| EPS | $-2.58 | – |
| Book Value/Share | $8.50 | – |
| FCF/Share | $-1.77 | – |
Profitability & Margins
| Metric | MBX | Rank |
|---|---|---|
| ROE | -25.5% | 28/38 |
| ROA | -23.9% | 32/43 |
| ROIC | -28.6% | 35/46 |
Financial Health
| Metric | MBX | Rank |
|---|---|---|
| Current Ratio | 18.08x | 8/59 |
| D/E Ratio | 0.06x | 42/48 |
| Financial Leverage | 1.06x | 42/48 |
| Working Capital | $404M | 45/59 |
Cash Flow
| Metric | MBX | Rank |
|---|---|---|
| Operating Cash Flow | -$83M | 42/59 |
| Free Cash Flow | -$85M | 35/50 |
| Capital Spending | -$3M | 15/50 |
Income Statement
| Metric | MBX | Rank |
|---|---|---|
| Operating Income | -$118M | 32/51 |
| Net Income | -$104M | 28/46 |
| R&D Expense | $88M | 55/58 |
Dividend & Shareholder Information
| Metric | MBX | Rank |
|---|---|---|
| Shares Outstanding | 48M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $428M | 98.1% of assets |
| Cash & Short-term Investments | $54M | 12.4% of assets |
| Total Liabilities | $26M | 6.0% of assets |
| Short-term Debt | $19M | 4.4% of assets |
Quarterly Financial Reports
MBX quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Mbx Biosciences, Inc. (MBX) industry peers
Companies classified under the same SEC industry code as Mbx Biosciences, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| MBX Mbx Biosciences, Inc. | ▲ | $2.39B |
| LLY Eli Lilly & Co | ▼ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▼ | $504.37B |
| MRK Merck & Co., Inc. | ▶ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.39B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▼ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $126.66B |
| BMY Bristol Myers Squibb Co | ▼ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.80B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▼ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▶ | $23.80B |
| UTHR United Therapeutics Corp | ▼ | $22.87B |
| VTRS Viatris Inc | ▼ | $21.43B |
| INSM Insmed Inc | ▶ | $21.02B |
| ASND Ascendis Pharma A/S | ▶ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▶ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▲ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.39B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.56B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.05B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▲ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $3.83B |
Where MBX sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Mbx Biosciences, Inc. (MBX) stock news
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
Welcome to everyone in the room and on webcast, and thank you for joining us for Obesity Day. Today, we are excited and honored to present our novel and transformative approach to treating this global ...
MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of ...
FAQ
Mbx Biosciences, Inc. (MBX) stock forecast FAQ
What is the Mbx Biosciences, Inc. (MBX) stock forecast?
Our AI ranks Mbx Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Mbx Biosciences, Inc. stock predictions?
For MBX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 5.0%, measured on 238 forecast dates between 2024-11-08 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 281 forecast dates between 2024-11-08 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Mbx Biosciences, Inc. forecasts updated?
Mbx Biosciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Mbx Biosciences, Inc.'s industry peers?
60 issuers in our coverage, MBX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.